- Home
- TNYA vs SWKH Comparison
TNYA vs SWKH Comparison
Compare TNYA & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- SWKH
- Stock Information
- Founded
- TNYA 2016
- SWKH 1996
- Country
- TNYA United States
- SWKH United States
- Employees
- TNYA N/A
- SWKH N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- SWKH Diversified Financial Services
- Sector
- TNYA Health Care
- SWKH Finance
- Exchange
- TNYA Nasdaq
- SWKH Nasdaq
- Market Cap
- TNYA 189.1M
- SWKH 176.0M
- IPO Year
- TNYA 2021
- SWKH 1999
- Fundamental
- Price
- TNYA $1.29
- SWKH $14.53
- Analyst Decision
- TNYA Strong Buy
- SWKH Strong Buy
- Analyst Count
- TNYA 5
- SWKH 1
- Target Price
- TNYA $8.60
- SWKH $18.00
- AVG Volume (30 Days)
- TNYA 3.0M
- SWKH 11.0K
- Earning Date
- TNYA 11-05-2025
- SWKH 11-13-2025
- Dividend Yield
- TNYA N/A
- SWKH N/A
- EPS Growth
- TNYA N/A
- SWKH 55.18
- EPS
- TNYA N/A
- SWKH 1.41
- Revenue
- TNYA N/A
- SWKH $37,409,000.00
- Revenue This Year
- TNYA N/A
- SWKH $52.93
- Revenue Next Year
- TNYA N/A
- SWKH N/A
- P/E Ratio
- TNYA N/A
- SWKH $10.34
- Revenue Growth
- TNYA N/A
- SWKH 47.31
- 52 Week Low
- TNYA $0.36
- SWKH $12.00
- 52 Week High
- TNYA $4.01
- SWKH $16.24
- Technical
- Relative Strength Index (RSI)
- TNYA 61.07
- SWKH 46.20
- Support Level
- TNYA $1.15
- SWKH $14.43
- Resistance Level
- TNYA $1.43
- SWKH $14.85
- Average True Range (ATR)
- TNYA 0.09
- SWKH 0.23
- MACD
- TNYA -0.01
- SWKH -0.01
- Stochastic Oscillator
- TNYA 63.13
- SWKH 12.99
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.